Table 1 Summary of the X-ray crystallographic data for complexes 2Phe, 2PhePh, 2Bn·CH3CN and 2Bn·CO
2Phe
2PhePh
2Bn·CH3CN
2Bn·CO
Empirical formula
Formula weight
Crystal system
C22H25N3CuClO4
494.46
C28H29N3CuClO4
570.55
Triclinic
C23H26N4CuPF6
567.00
Monoclinic
P21/c (14)
14.380(2)
7.196(2)
C22H23N3O5CuCl
508.43
Monoclinic
P21/n (14)
11.7088(3)
14.6661(5)
12.4843(4)
Triclinic
¯
Space group (no.)
P1 (1)
P1 (2)
˚
a/A
7.715(4)
8.887(6)
9.361(6)
83.77(3)
88.29(2)
75.93(3)
618.9(6)
1
11.159(2)
17.147(2)
12.387(2)
88.88(1)
109.24(1)
91.35(1)
2237.0(6)
4
˚
b/A
˚
c/A
25.291(4)
a/◦
b/◦
c /◦
V/A
Z
93.147(1)
99.58(1)
3
˚
2140.6(1)
4
1024.00
1.534
2580.6(9)
4
1160.00
1.459
F(000)
296.00
1.531
1048.00
1.510
Dc/g cm−3
T/◦C
−115
−115
22
−120
Crystal size/mm
l(Mo-Ka)/cm−1
Diffractometer
0.20 × 0.20 × 0.10
11.80
0.40 × 0.10 × 0.10
10.32
0.30 × 0.25 × 0.15
0.40 × 0.25 × 0.25
11.35
9.70
Rigaku
Rigaku
Rigaku
R-axis IV
Mo-Ka (0.71070)
51.4
Rigaku
R-axis IV
Mo-Ka (0.71070)
51.6
RAXIS-RAPID
Mo-Ka (0.71069)
54.9
RAXIS-RAPID
Mo-Ka (0.71075)
55.0
˚
Radiation (k/A)
◦
2hmax
/
No. reflns. measd.
No. reflns. obsd.
No. variables
Ra,c
20832
3791 [I > 3.0r(I)]
305
0.044
0.072
1.48
5544
2636 [I > 0.1r(I)]
364
0.058
0.063
1.098
4365
3616 [I > 3.0r(I)]
317
0.087
0.132
1.91
7193
6582 [I > 3.0r(I)]
577
0.044
0.073
1.39
b,d
Rw
GOF
ꢀ
ꢀ
ꢀ
ꢀ
2
2
2
a R = [|Fo| − |Fc|]/ |Fo| (I ≥ 3.0r(I) for 2Phe and I ≥ 0.1r(I) for 2PhePh). b Rw = { w(|Fo| − |Fc|)2/ wFo
}
1/2; w = 1/[0.001|Fo| + 3.0r|Fo| +
ꢀ
ꢀ
ꢀ
ꢀ
0.10] for 2Phe and 2PhePh
.
c R = [|Fo| − |Fc|]/ |Fo| (I ≥ 2.0r(I) for 2Bn·MeCN and I ≥ 3.0r(I) for 2Bn·CO). d Rw = [ w(|Fo| − |Fc|)2/ w|Fo| ]1/2
;
2
2
w = 1/[r2(Fo) + p2|Fo| /4] (p = 0.081 for 2Bn·MeCN and p = 0.098 for 2Bn·CO).
adding conc. HCl and the solvent was removed by evaporation.
To the resulting material was added 15% NaOH aqueous
solution (100 mL), and the organic materials were extracted
with CHCl3 (50 mL × 3). After drying over anhydrous K2CO3,
evaporation of the solvent gave a brown residue, from which
ligand L2Phe was isolated as a yellow oily material by SiO2
column chromatography. Yield: 2.9 g (88%). 1H NMR (600 Hz,
CD2Cl2): d 2.49 (6 H, s, –CH3), 2.77 (2 H, dd, J = 8.0 and
above for the synthesis of L2Phe using benzylamine instead of
2-phenylethylamine. Yield: 42%. 1H NMR (400 MHz, CDCl3):
d 2.51 (6 H, s, –CH3), 3.68 (2 H, s, –CH2Ph), 3.78 (4 H, s,
–CH2Py), 6.99 (2 H, d, J = 7.5 Hz, HPy-5), 7.19–7.33 (3 H, m,
HPh), 7.42 (2 H, d, J = 7.5 Hz, HPy-3), 7.45 (2 H, d, J = 8.1 Hz,
HPh), 7.55 (2 H, t, J = 7.5 Hz, HPy-4). Anal. Calc. for C21H23N3:
C, 79.46; H, 7.30; N, 13.24%. Found: C, 79.49; H, 7.37; N,
13.13%. FAB-MS (+): m/z 318 (L + H). FT-IR/cm−1 (KBr
=
=
6.9 Hz, –NCH2CH2Ph), 2.85 (2 H, dd, J = 8.0 and 6.9 Hz,
–NCH2CH2Ph), 3.81 (4 H, s, –NCH2Py), 6.99 (2 H, d, J =
7.6 Hz, HPy-5), 7.12 (2 H, d, J = 7.5 Hz, HPh-2 and HPh-6), 7.17 (1
H, t, J = 7.5 Hz, HPh-4), 7.20 (2 H, d, J = 7.6 Hz, HPy-3), 7.24
(2 H, t, J = 7.5 Hz, HPh-3 and HPh-5), 7.48 (2 H, t, J = 7.6 Hz,
HPy-4). 13C NMR (600 Hz, CD2Cl2): d 24.53 (–CH3), 33.86
(–NCH2CH2Ph), 56.45 (–NCH2CH2Ph), 60.76 (–NCH2Py),
119.87 (CPy-3), 121.44 (CPy-5), 126.15 (CPh-4), 128.51 (CPh-3 and
CPh-5), 129.28 (CPh-2 and CPh-6), 136.75 (CPy-4), 141.22 (CPh-1),
157.86 (CPy-6), 159.74 ppm (CPy-2). FAB-MS (+); m/z 332.19
(L + H).
disk): 1591 (C C, aromatic), 1578 (C C, aromatic).
CAUTION! The perchlorate salts employed in this study are all
potentially explosive and should be handled with care.
[CuI(L2Phe)]ClO4 (2Phe). Ligand L2Phe (99.4 mg, 0.3 mmol)
was treated with [CuI(CH3CN)4]ClO4 (96.1 mg, 0.3 mmol) in
CH2Cl2 (5 mL) under Ar atmosphere (in a glove box). After
stirring for 30 min at room temperature, insoluble materials
were removed by filtration. Addition of ether (100 mL) to the
filtrate gave a white powder that was precipitated by standing the
mixture for several minutes. The supernatant was then removed
by decantation, and the remained pale brown solid was washed
with ether three times, and dried. Yield: 114 mg (77%). All
procedures were done in a glove box (DBO-1KP, Miwa Co. Ltd.)
([O2] < 0.1 ppm). 1H NMR (600 MHz, CD2Cl2): d 2.56 (6 H, s, –
CH3), 2.83 (2 H, t, J = 6.2 Hz, –NCH2CH2Ph), 3.13 (2 H, d, J =
6.2 Hz, –NCH2CH2Ph), 3.88 (2 H, d, J = 16.0 Hz, –NCHHPy),
4.20 (2 H, d, J = 16.0 Hz, –NCHHPy), 6.95 (2 H, d, J = 7.3 Hz,
HPh-2 and HPh-6), 7.24 (2 H, d, J = 7.7 Hz, HPy-3), 7.28 (2 H, d,
J = 7.7 Hz, HPy-5), 7.33 (2 H, t, J = 7.3 Hz, HPh-3 and HPh-5), 7.43
N,N-Bis(6-methylpyridin-2-ylmethyl)-2,2-diphenylethylamine
(L2PhePh). This ligand was prepared by the same procedure
described above for the synthesis of L2Phe using 2,2-
diphenylethylamine instead of 2-phenylethylamine. Yield:
37%. 1H NMR (600 Hz, CD2Cl2): d 2.50 (6 H, s, –CH3), 3.18 (2
H, d, J = 7.8 Hz, –NCH2CHPh2), 3.80 (4 H, s, –NCH2Py), 4.36
(1 H, t, J = 7.8 Hz, –NCH2CHPh2), 6.89 (2 H, d, J = 7.6 Hz,
HPy-3), 6.99 (2 H, d, J = 7.6 Hz, HPy-5), 7.12 (4 H, d, J = 7.2 Hz,
HPh-2 and HPh-6), 7.19 (2 H, t, J = 7.2 Hz, HPh-4), 7.25 (4 H, t, J =
7.6 Hz, HPh-3 and HPh-5), 7.40 (2 H, t, J = 7.6 Hz, HPy-4). 13C NMR
(600 Hz, CD2Cl2): d 24.54 (–CH3), 49.84 (–NCH2CHPh2),
59.84 (–NCH2CHPh2), 61.06 (–NCH2Py), 120.26 (CPy-3), 121.46
(CPy-5), 126.54 (CPh-4), 128.58 (CPh-3 and CPh-5), 128.75 (CPh-2 and
CPh-6), 136.66 (CPy-4), 144.16 (CPh-1), 157.71 (CPy-6), 159.37 ppm
(CPy-2). FAB-MS (+): m/z 408.2 (L + H).
(1 H, t, J = 7.3 Hz, HPh-4), 7.75 (2 H, t, J = 7.7 Hz, HPy-4). 13
C
NMR (600 Hz, CD2Cl2): d 27.36 (–CH3), 33.94 (–NCH2CH2Ph),
56.27 (–NCH2CH2Ph), 59.70 (–NCH2Py), 121.80 (CPy-3), 122.61
(CPh-2 and CPh-6), 124.59 (CPy-5), 127.80 (CPh-3 and CPh-5), 128.29
(CPh-4), 138.12 (CPh-1), 139.27 (CPy-4), 157.26 (CPy-2), 157.94 ppm
(CPy-6). FT-IR/cm−1 (KBr disk): 1109, 1090 and 625 (ClO4−).
ESI-MS (+): m/z 394.4 (M+). Anal. Calc. for C22H26O4.5N3CuCl:
C, 52.48; H, 5.21; N, 8.35. Found: C, 52.85; H, 5.05; N, 8.46%.
N,N-Bis(6-methylpyridin-2-ylmethyl)benzylamine
(L2Bn ).
This ligand was prepared by the same procedure described
3 5 1 6
D a l t o n T r a n s . , 2 0 0 5 , 3 5 1 4 – 3 5 2 1